male or female, between the ages of 18 and 60 years

subject is able to learn and self-administer subcutaneous injections (a care-giver may be trained to inject the subject)

subjects must have a current diagnosis of relapsing remitting multiple sclerosis (rrms) (according to the 2010 mcdonald ms diagnostic criteria)

other protocol defined inclusion criteria could apply

any multiple sclerosis categorized as primary progressive, secondary progressive or progressive relapsing

allergy to mannitol, plovamer acetate, copaxone (glatiramer acetate), gd contrast for mri

any requirement for continuous systemic glucocorticoid administration during the trial period. (note: treatment with interferons such as avonex®, rebif®, or betaseron® will be allowed until the baseline visit, as no wash-out period is needed)

contraindication to copaxone use

other protocol defined exclusion criteria could apply